enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Side effects of bicalutamide - Wikipedia

   en.wikipedia.org/wiki/Side_effects_of_bicalutamide

   [45] [46] Moreover, the lifetime incidence of breast cancer in men is approximately 0.1%, [47] the average age of diagnosis of prostate cancer and male breast cancer are similar (around 70 years), [10] [48] and millions of men have been treated with bicalutamide for prostate cancer, [49] all of which are potentially in support of the notion of ...

3. Medical uses of bicalutamide - Wikipedia

   en.wikipedia.org/wiki/Medical_uses_of_bicalutamide

   Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...

4. Bicalutamide - Wikipedia

   en.wikipedia.org/wiki/Bicalutamide

   Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. [10] It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC).

5. Prostate cancer shouldn’t be a death sentence. But for a ...

   www.aol.com/finance/prostate-cancer-shouldn-t...

   In fact, the five-year survival rate for prostate cancer detected early is virtually 100%, Siddiqui says. The outlook for late-diagnosed patients, however, is not nearly as rosy. There is no ...

6. Early Prostate Cancer (clinical programme) - Wikipedia

   en.wikipedia.org/wiki/Early_Prostate_Cancer...

   The EPC programme found that bicalutamide was effective in treating locally advanced prostate cancer. [2] Conversely, it was not effective for localized prostate cancer, where there was instead a statistically insignificant trend toward reduced overall survival with bicalutamide therapy (at median 7.4 years follow-up: HR Tooltip hazard ratio ...

7. Comparison of bicalutamide with other antiandrogens

   en.wikipedia.org/wiki/Comparison_of_bicalutamide...

   Bicalutamide also shows a better safety profile than cyproterone acetate. When used as a high-dosage monotherapy, bicalutamide shows slightly inferior effectiveness in the treatment of prostate cancer compared to castration and GnRH analogues but a different and potentially superior tolerability and safety profile.